Calithera Biosciences, Inc. News Releases http://ir.calithera.com/ Calithera Biosciences, Inc. News Releases en Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights http://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-reports-first-quarter-2019-financial --Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on May 9, 2019 -- SOUTH SAN FRANCISCO, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company pioneering the discovery and development of Thu, 09 May 2019 16:06:00 -0400 Calithera Biosciences, Inc. News Releases 8951 Calithera Biosciences to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019 http://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-report-first-quarter-2019-financial SOUTH SAN FRANCISCO, Calif. , May 03, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways, announced today that the Company’s first Fri, 03 May 2019 07:05:00 -0400 Calithera Biosciences, Inc. News Releases 8941 Calithera Biosciences Presents New Preclinical Data for CB-708 at AACR Annual Meeting 2019 http://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-presents-new-preclinical-data-cb-708-aacr Oral CD73 inhibitor enhances the effect of checkpoint blockade and chemotherapy SOUTH SAN FRANCISCO, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for Tue, 02 Apr 2019 07:05:00 -0400 Calithera Biosciences, Inc. News Releases 8911 Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib http://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-initiates-phase-12-trial-telaglenastat Study is part of clinical trial collaboration with Pfizer SOUTH SAN FRANCISCO, Calif. , March 26, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer Tue, 26 Mar 2019 07:05:00 -0400 Calithera Biosciences, Inc. News Releases 8906 Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights http://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-reports-fourth-quarter-2018-financial -Calithera to Provide Corporate Update via Conference Call and Webcast at 1:30 p.m. PT on March 7, 2019 SOUTH SAN FRANCISCO, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel Thu, 07 Mar 2019 16:06:00 -0500 Calithera Biosciences, Inc. News Releases 8871 Calithera to Present at Cowen & Company 39th Annual Healthcare Conference http://ir.calithera.com/news-releases/news-release-details/calithera-present-cowen-company-39th-annual-healthcare SOUTH SAN FRANCISCO, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Tue, 05 Mar 2019 07:05:00 -0500 Calithera Biosciences, Inc. News Releases 8861 Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019 http://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-report-fourth-quarter-2018-financial SOUTH SAN FRANCISCO, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Mon, 04 Mar 2019 07:05:00 -0500 Calithera Biosciences, Inc. News Releases 8851 Calithera Biosciences Announces CB-708 Preclinical Data Presentation at the AACR Annual Meeting 2019 http://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-announces-cb-708-preclinical-data SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Wed, 27 Feb 2019 16:35:00 -0500 Calithera Biosciences, Inc. News Releases 8846 Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference http://ir.calithera.com/news-releases/news-release-details/calithera-participate-8th-annual-svb-leerink-global-healthcare SOUTH SAN FRANCISCO, Calif. , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Fri, 22 Feb 2019 08:00:00 -0500 Calithera Biosciences, Inc. News Releases 8836 Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis http://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-initiates-phase-1-trial-arginase-inhibitor SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Thu, 21 Feb 2019 16:05:00 -0500 Calithera Biosciences, Inc. News Releases 8831